Table 2.

Toxicity of LPAAT-β inhibitor (CT-32228) in athymic mice

DayControlDMSO vehicleLPAAT-β inhibitor
18 mg/kg36 mg/kg72 mg/kg
WBC (1,000/μL)01.1 ± 0.31.6 ± 0.81.3 ± 0.41.1 ± 0.51.0 ± 0.3
71.1 ± 0.20.7 ± 0.40.8 ± 0.30.7 ± 0.50.3 ± 0.0
141.7 ± 0.52.9 ± 3.51.3 ± 0.32.0 ± 1.1
210.5 ± 0.11.1 ± 1.20.7 ± 0.51.2 ± 0.2
Hemoglobin (g/dL)012.5 ± 0.713.4 ± 0.913.0 ± 0.613.2 ± 0.711.8 ± 1.9
714.5 ± 1.114.6 ± 1.413.9 ± 0.812.4 ± 3.812.2 ± 0.0
1414.8 ± 1.513.4 ± 1.913.9 ± 0.713.5 ± 0.4
2111.2 ± 1.09.2 ± 2.710.6 ± 0.58.2 ± 2.0
Platelets (1,000/μL)01,210 ± 1611,304 ± 95.41,270 ± 157.11,072 ± 215.71,172 ± 109.3
71,101 ± 1611,221 ± 212.71,258 ± 334.61,133 ± 335.11,074 ± 0.0
141,127 ± 231,022 ± 459.01,517 ± 194.81,379 ± 808.2
21774 ± 260781 ± 441.01,118 ± 148.5679.5 ± 324.6
Aspartate transaminase (IU/L)0272.3 ± 23.5
7143.8 ± 43.6201 ± 81.0137.2 ± 17.5274.2 ± 101.0637 ± 408.7
14182.3± 46.6204 ± 125.4103 ± 24.0
21110.7 ± 18.1142 ± 52.4102.5 ± 17.9
Alanine transaminase (IU/L)060.8 ± 8.1
7144.8 ± 109.6145.6 ± 92.5128.6 ± 62.5121.4± 27.6229 ± 165.5
1482.2 ± 33.782.8 ± 30.844.3 ± 20.3
2131.4 ± 3.842.8 ± 6.449 ± 29.3
Creatinine (mg/dL)00.5 ± 0.0
70.3 ± 0.10.30 ± 0.10.30 ± 0.00.30 ± 0.00.3 ± 0.0
140.2 ± 0.00.30 ± 0.10.30 ± 0.1
210.4 ± 0.10.40 ± 0.00.45 ± 0.1
Weight (g)019.6 ± 3.020.6 ± 1.822.9 ± 1.921.9 ± 1.821.8 ± 1.1
719.5 ± 3.219.8 ± 1.121.1 ± 0.918.4 ± 2.017.9 ± 0.8*
1420.6 ± 3.620.6 ± 1.222.3 ± 0.9
2121.1 ± 3.621.2 ± 1.623.0 ± 0.6
  • NOTE: Hematologic, hepatic, renal toxicities, and weight as an assessment of general health in untreated control mice, mice treated with DMSO, or mice treated with 18, 36, and 72 mg/kg of LPAAT-β inhibitor daily × 5 for 4 weeks (total 20 doses).

  • * Measurement taken on day 5. No mice from this group survived to day 7.